Compare FBK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBK | NRIX |
|---|---|---|
| Founded | 1906 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2016 | 2020 |
| Metric | FBK | NRIX |
|---|---|---|
| Price | $55.00 | $26.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $64.50 | $30.50 |
| AVG Volume (30 Days) | 230.8K | ★ 1.0M |
| Earning Date | 04-13-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $41.72 | N/A |
| Revenue Next Year | $7.21 | $48.05 |
| P/E Ratio | $25.44 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $49.74 | $8.20 |
| 52 Week High | $62.66 | $28.23 |
| Indicator | FBK | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 52.95 |
| Support Level | $55.29 | $14.63 |
| Resistance Level | $56.77 | $28.23 |
| Average True Range (ATR) | 1.07 | 1.02 |
| MACD | -0.30 | -0.26 |
| Stochastic Oscillator | 18.70 | 34.45 |
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates majority of revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.